Enteral Activation of WR-2721 Mediates Radioprotection and Improved Survival from Lethal Fractionated Radiation

[1]  T. Conroy,et al.  Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas. , 2018, Journal of Clinical Oncology.

[2]  J. Vauthey,et al.  Management of unresectable intrahepatic cholangiocarcinoma: how do we decide among the various liver-directed treatments? , 2017, Hepatobiliary surgery and nutrition.

[3]  C. Taniguchi,et al.  Dose escalation with an IMRT technique in 15 to 28 fractions is better tolerated than standard doses of 3DCRT for LAPC , 2017, Advances in radiation oncology.

[4]  B. Eisenberg.  Faculty Opinions recommendation of Treatment guidelines for preoperative radiation therapy for retroperitoneal sarcoma: preliminary consensus of an international expert panel. , 2016 .

[5]  W. Ichikawa,et al.  Early tumor shrinkage as a predictor of favorable outcomes in patients with advanced pancreatic cancer treated with FOLFIRINOX , 2016, Oncotarget.

[6]  D. Gourlay,et al.  Intestinal alkaline phosphatase: a summary of its role in clinical disease. , 2016, The Journal of surgical research.

[7]  Gabriel O Sawakuchi,et al.  Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation. , 2016, International journal of radiation oncology, biology, physics.

[8]  R. Abrams,et al.  Treatment Guidelines for Preoperative Radiation Therapy for Retroperitoneal Sarcoma: Preliminary Consensus of an International Expert Panel. , 2015, International journal of radiation oncology, biology, physics.

[9]  K. Mason,et al.  Polymer complex of WR 2721. Synthesis and radioprotective efficiency. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[10]  M. Scorsetti,et al.  Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach , 2014, BMC Cancer.

[11]  M. Katz,et al.  Management of borderline resectable pancreatic cancer. , 2014, Seminars in radiation oncology.

[12]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[13]  Shengqi Wang,et al.  Design and evaluation of biodegradable enteric microcapsules of amifostine for oral delivery. , 2013, International journal of pharmaceutics.

[14]  M. Bermejo,et al.  Ion-pair strategy for enabling amifostine oral absorption: rat in situ and in vivo experiments. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[15]  L. Chin,et al.  Recapitulating human cancer in a mouse , 2013, Nature Biotechnology.

[16]  Hong Wang,et al.  Why Can’t Rodents Vomit? A Comparative Behavioral, Anatomical, and Physiological Study , 2013, PloS one.

[17]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[18]  A. Koong,et al.  A dosimetric model of duodenal toxicity after stereotactic body radiotherapy for pancreatic cancer. , 2010, International journal of radiation oncology, biology, physics.

[19]  S. Korsmeyer,et al.  p53 Controls Radiation-Induced Gastrointestinal Syndrome in Mice Independent of Apoptosis , 2009, Science.

[20]  G. Dijkstra,et al.  Role of alkaline phosphatase in colitis in man and rats , 2008, Gut.

[21]  T. Mandal,et al.  Radioprotection in mice following oral administration of WR-1065/PLGA nanoparticles , 2008, International journal of radiation biology.

[22]  C. N. Coleman,et al.  Intrarectal amifostine suspension may protect against acute proctitis during radiation therapy for prostate cancer: a pilot study. , 2006, International journal of radiation oncology, biology, physics.

[23]  J. Millán.  Alkaline Phosphatases , 2006, Purinergic Signalling.

[24]  L. Chin,et al.  High-resolution characterization of the pancreatic adenocarcinoma genome , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[25]  R. DePinho,et al.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. , 2003, Genes & development.

[26]  D. Brizel,et al.  Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  C. Baird.  The pilot study. , 2000, Orthopedic nursing.

[28]  M. Anscher,et al.  Topical application of WR‐2721 to prevent radiation‐induced proctosigmoiditis. A phase I/II trial , 1992, Cancer.

[29]  M. Goitein,et al.  Tolerance of normal tissue to therapeutic irradiation. , 1991, International journal of radiation oncology, biology, physics.

[30]  J. Ward,et al.  Radioprotection of cells in culture by WR-2721 and derivatives: form of the drug responsible for protection. , 1988, Cancer research.

[31]  J. Glick,et al.  Toxicity of WR-2721 administered in single and multiple doses. , 1984, International journal of radiation oncology, biology, physics.

[32]  R. Caldwell,et al.  Acute cardiovascular and autonomic effects of WR-2721: a radioprotective compound. , 1975, Radiation research.

[33]  L. Smith,et al.  Some pharmacologic effects of WR-2721: their role in toxicity and radioprotection. , 1973, Radiation research.

[34]  J. Millán.  Structure, substrate specificity and functional relatedness to other members of a large superfamily of enzymes , 2006 .

[35]  S. J. Holt,et al.  The effect of increased crypt cell proliferation on the activity and subcellular localization of esterases and alkaline phosphatase in the rat small intestine , 2005, The Histochemical Journal.

[36]  I. Kaplan,et al.  Intrarectal application of amifostine for the prevention of radiation-induced rectal injury. , 2002, Seminars in radiation oncology.

[37]  L. Milas,et al.  WR-2721 reduces intestinal toxicity from concurrent gemcitabine and radiation treatment , 2001, International journal of pancreatology : official journal of the International Association of Pancreatology.

[38]  F. Courteille,et al.  Radioprotective activity of ethylcellulose microspheres containing WR 2721, after oral administration. , 1987, International journal of radiation biology and related studies in physics, chemistry, and medicine.

[39]  H. Withers,et al.  Microcolony survival assay for cells of mouse intestinal mucosa exposed to radiation. , 1970, International journal of radiation biology and related studies in physics, chemistry, and medicine.